Boekhorst Paul Francis Olivier Te
President and CEO at ImmuCell Corporation
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 10 months
- Director since
- 2025
10 months of board service in total across 1 board, counting each seat separately. Longest: ImmuCell Corporation, 10 months.
Chief executive roles
Mixed · grade D
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 59
4.3% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | ImmuCell Corporation | Open-market purchase | +8,000 | $9.50 | $76,000 |
| Dec 3, 2025 | ImmuCell Corporation | Open-market purchase | +2,556 | $5.00 | $12,780 |
| Dec 3, 2025 | ImmuCell Corporation | Open-market purchase | +3,521 | $5.04 | $17,746 |
| Dec 2, 2025 | ImmuCell Corporation | Open-market purchase | +3,708 | $4.87 | $18,058 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.